Ginsenoside Ra3
Based on 1 Customer Validation
Ginsenoside Ra3 is an OATP1B1/OATP1B3 inhibitor that blocks organic anion-transporting polypeptide-mediated cellular uptake. Ginsenoside Ra3 targets PIK3CA (the catalytic subunit of phosphatidylinositol 3-kinase) and PIK3CG (the catalytic subunit of phosphatidylinositol 3-kinase γ), both of which are components of the PI3K/Akt/mTOR pathway. Ginsenoside Ra3 targets AR, an androgen receptor that regulates PSA expression. Ginsenoside Ra3 inhibits platelet aggregation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.91%
- CAS 番号: 90985-77-6
- 分子式: C59H100O27
- 分子量:1241.41
-
保管条件:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
|
OATP1B1 |
OATP1B3 |
PIK3CA |
PIK3CG |
PI3K |
Akt |
mTOR |
AR |
体外実験
Ginsenoside Ra3 (10 μM; 20 h) yields only low and trace ginsenoside Rd with rat liver homogenate, no Ginsenoside Rd (HY-N0043) with rat liver cytosol, and similar inter-compound differences with human liver cytosol[1].
Ginsenoside Ra3 (5-50 μM; 24 h) has a rat plasma unbound fraction of 0.92% and a human plasma unbound fraction of 4.0%[1].
Ginsenoside Ra3 (100 μM; 10 min) inhibits human OATP1B1 and OATP1B3 in transfected HEK-293 cells with IC50 values of 4.9 μM and 2.9 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
| Species | Dose | Route | Cmax | AUC0-t | T1/2 | Vss |
|---|---|---|---|---|---|---|
| Rat[1] | 10 mL/kg | i.v. | 3.54 μM | 23.1 μM·h | 18.1 h | 242 mL/kg |
化学情報
-
CAS 番号 90985-77-6
-
性状 Solid
-
分子量 1241.41
-
分子式 C59H100O27
-
Color White to off-white
-
SMILES
CC12C3(C(C(O)CC1C4(C(C(C)(C(OC5C(C(C(O)C(CO)O5)O)OC6OC(C(O)C(O)C6O)CO)CC4)C)CC2)C)C(C(CC/C=C(C)/C)(C)OC7OC(C(O)C(O)C7O)COC8C(C(C(O)C(CO)O8)OC9C(C(C(O)CO9)O)O)O)CC3)C
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (40.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (1.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (1.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (292 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL | 20.1384 mL |
| 5 mM | 0.1611 mL | 0.8055 mL | 1.6111 mL | 4.0277 mL | |
| 10 mM | 0.0806 mL | 0.4028 mL | 0.8055 mL | 2.0138 mL | |
| 15 mM | 0.0537 mL | 0.2685 mL | 0.5370 mL | 1.3426 mL | |
| 20 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 1.0069 mL | |
| 25 mM | 0.0322 mL | 0.1611 mL | 0.3222 mL | 0.8055 mL | |
| 30 mM | 0.0269 mL | 0.1343 mL | 0.2685 mL | 0.6713 mL | |
| 40 mM | 0.0201 mL | 0.1007 mL | 0.2014 mL | 0.5035 mL |
Ginsenoside Ra3 関連分類
HY-N4259 関連分類
Powered by Bioz